Author Interviews, Lyme, Race/Ethnic Diversity, UCLA / 18.10.2021

MedicalResearch.com Interview with: Dan P. Ly M.D., Ph.D., M.P.P. Division of General Internal Medicine and Health Services Research David Geffen School of Medicine at UCLA Los Angeles, CA  MedicalResearch.com: What is the background for this study? Response: Lyme disease presents first on the skin with the classic “bull’s-eye” rash. But such rashes in Black patients aren’t well-represented in medical textbooks. This may lead to physicians not recognizing such rashes in Black patients. As a result, Black patients are more likely to present with later complications of Lyme disease when first diagnosed such as neurologic complications.   (more…)
Author Interviews, COVID -19 Coronavirus, Dermatology, Respiratory / 06.10.2021

MedicalResearch.com Interview with: Lara van der Schoot  MD, PhD candidate Department of Dermatology Radboud University Medical Center Nijmegen, The Netherlands MedicalResearch.com: What is the background for this study? Response: Psoriasis is a chronic, immune mediated skin disease for which effective targeted biological agents have become available the past years. Inherent to their immunomodulatory mechanism of action, biologics might increase infections risk. We know from clinical trial data that respiratory tract infections are among the most common adverse events during biologic treatment, but real-world data is sparse. Regarding the risk of serious infections among biologic users, mostly defined as infections requiring hospitalization, previous studies provided different results and there is limited comparative data for the newer biologics available. The COVID-19 pandemic turned attention to the risk of infections among biologic users, especially for respiratory tract infections, as they might relate to susceptibility for viral respiratory tract infections such as COVID-19. In our study, the primary aim was to determine the risk of respiratory tract infections among real-world psoriasis patients treated with biologics, including the newer IL-17 and IL-23 inhibitors. The secondary aim was to assess risk of serious infections in this cohort. Additionally, rates of SARS-CoV-2 infections were assessed. (more…)
Author Interviews, HIV, Infections, Vanderbilt / 02.10.2021

MedicalResearch.com Interview with: Rachael Pellegrino, MD Vanderbilt University Medical Center MedicalResearch.com: What is the background for this study? Response: We know that HIV care and outcomes have dramatically improved over the last 20 years, but disparities still exist at each step of the HIV care continuum, which can ultimately lead to differences in mortality rates. In addition to assessing trends and disparities in mortality, we wanted to look at differences in premature mortality, which has not been widely studied in the HIV population in the US. This concept serves to emphasize and quantify the time lost by death at an early age as an important measurement of the impact of diseases and can expose disparities that are not apparent in the mortality rates alone. (more…)
Author Interviews, Critical Care - Intensive Care - ICUs, Infections / 02.10.2021

MedicalResearch.com Interview with: Chanu Rhee, MD, MPH Harvard Medical School and Harvard Pilgrim Health Institute Boston, MA MedicalResearch.com: What is the background for this study? Response: Sepsis is a leading cause of death, disability, and healthcare costs.  This has triggered regulators and hospitals to invest heavily in improving sepsis recognition and care.  Most notably, the Centers for Medicare & Medicaid Services (CMS) implemented the Severe Sepsis/Septic Shock Early Management Bundle (SEP-1) by the in October 2015.  SEP-1 requires hospitals to report compliance with a 3 and 6 hour sepsis care bundle, which includes initial and repeat lactate measurements, blood culture orders, broad-spectrum antibiotic, specific quantities of fluid boluses for hypotension, vasopressors for persistent hypotension, and documentation of a repeat volume and perfusion assessment for patients with septic shock. While SEP-1 has helped raise awareness of sepsis and catalyzed sepsis quality improvement initiatives around the country, concerns have been raised about its potential unintended consequences -- particularly around increasing unnecessary broad spectrum antibiotic use -- and the strength of evidence supporting the measure.  In this study, we used detailed clinical data from a diverse cohort of hospitals to assess whether SEP-1 implementation was associated with changes in key processes of care and mortality in patients with suspected sepsis.  (more…)
Author Interviews, HPV, Vaccine Studies / 01.10.2021

MedicalResearch.com Interview with: Holly Frost, MD Assistant Professor Pediatrics University of Colorado Anschutz School of Medicine Thersia Sebastian, MD Pediatrics, Denver Health  MedicalResearch.com: What is the background for this study? Response: Among children with acute otitis media (AOM) S.pneumoniae, H.influenzae, and M.catarrhalis are the predominant bacterial otopathogens. Historically, the gold standard for diagnosing otopathogens has been through middle ear fluid (MEF) culture. The challenge with MEF culture is that it is time-consuming and requires expert training often only done by specialists, thereby limiting its diagnostic utility to guide routine clinical care. Recent studies have shown that there is a high correlation between nasopharyngeal (NP) and MEF organisms during AOM. It is easier to collect NP swabs and less training is required. Thus, NP samples could serve as a surrogate for detection of otopathogens, potentially making identification of otopathogens practical and feasible in a typical practice environment compared to a MEF collection. Identification of otopathogens could be critical in treatment management of AOM, especially in the era of antimicrobial stewardship efforts to overall reduce unnecessary antibiotic use. Our goal was to compare the sensitivity and specificity of NP PCR to NP culture for common bacteria that cause ear infections.  (more…)
Author Interviews, CDC, COVID -19 Coronavirus, Vaccine Studies / 30.09.2021

MedicalResearch.com Interview with: Anne Hause PhD Epidemiologist Centers for Disease Control and Prevention  MedicalResearch.com: What is the background for this study? Response: On August 12, 2021, the Food and Drug Administration (FDA) amended Emergency Use Authorizations (EUA) for the Pfizer-BioNTech and Moderna COVID-19 vaccines to authorize administration of an additional dose following completion of a primary vaccination series to eligible persons with moderate to severe immunocompromise.  (more…)
Author Interviews, COVID -19 Coronavirus, Pediatrics, Vaccine Studies / 28.09.2021

MedicalResearch.com Interview with: Jonathan Baktari, MD CEO of e7health.com Dr. Baktari, CEO discusses Pfizer’s recent announcement that their vaccine trial for children ages 5-11 has been safe and effective, marking a major milestone in the fight against COVID-19.   MedicalResearch.com: What risks should parents weigh? Response: Pfizer has already said that based on their studies the lower dose two shot COVID vaccine for children is safe, meaning that their data shows minimal side effects. If that data is correct, then we should expect the same minor symptoms we see with teenagers to the COVID vaccine  (more…)
Author Interviews, CMAJ, COVID -19 Coronavirus, Pediatrics / 27.09.2021

MedicalResearch.com Interview with: Shaun K. Morris MD, MPH, FRCPC, FAAP, DTM&H Divisions of General Pediatrics Clinician-Scientist, Division of Infectious Diseases Division of Infectious Diseases at the Hospital for Sick Children (SickKids) for the Canadian Paediatric Surveillance Program COVID-19 Study Team MedicalResearch.com: What is the background for this study? Response: The SARS-CoV-2 virus can cause the disease we now call COVID-19. In early 2020, when the SARS-CoV-2 virus first spread outside of China, it quickly became apparent that cases may be seen in Canada. It was not known at the time how infection with the virus would affect children and youth. Because more severe disease from other respiratory viruses often disproportionally affect the very young, we expected that a similar pattern may be seen with SARS-CoV-2. We also did not know if children and youth with certain underlying medical conditions may be at higher risk for more severe disease. Ultimately, this study was designed to get a better understanding of how often children and youth in Canada are hospitalized with SARS-CoV-2 infection, how often severe disease happens, and which children or youth may be at higher risk for severe disease.      (more…)
Author Interviews, CDC, JAMA, Sexual Health, STD, USPSTF / 21.09.2021

MedicalResearch.com Interview with: Martha Kubik, Ph.D., R.N. Professor, School of Nursing College of Health and Human Services George Mason University Member, U.S. Preventive Services Task Force MedicalResearch.com: What is the background for this study? Are these infections increasing in incidence in the US? Response: Chlamydia and gonorrhea are two of the most common sexually transmitted infections in the U.S. More people are being diagnosed with both of these STIs than ever, with nearly 2 million cases of chlamydia and more than 600,000 cases of gonorrhea reported in 2019, according to the CDC. Because most do not have symptoms, screening is vitally important to help ensure that these infections are discovered and treated, and serious health complications prevented. (more…)
Author Interviews, CDC, COVID -19 Coronavirus, Vaccine Studies / 17.09.2021

MedicalResearch.com Interview with: Scott Pauley Press Officer, News Media Branch Division of Public Affairs Office of the Associate Director for Communication MedicalResearch.com: What is the background for this study?
  • In this real-world study of vaccine effectiveness:
    • Researchers compared hospitalized patients who tested positive for the virus that causes COVID-19 (case patients) to hospitalized patients who tested negative for the virus (control patients)
    • Vaccine effectiveness was calculated for each type of vaccine by comparing the proportion of cases patients and control patients vaccinated
    • 3,689 patients were included (1,682 case-patients and 2,007 control-patients)
Vaccination status breakdown: 2,362 unvaccinated; 476 fully vaccinated with Moderna; 738 fully vaccinated with Pfizer-BioNTech; and 113 fully vaccinated with Janssen vaccine. (more…)
Author Interviews, CDC, HPV, JAMA, Vaccine Studies / 17.09.2021

MedicalResearch.com Interview with: Kalyani Sonawane, PhD Assistant Professor of Management, Policy and Community Health UTHealth School of Public Health in Houston MedicalResearch.com: What is the background for this study? Response: Safety concern regarding the HPV vaccine is one of the most significant barriers to vaccination. Our objective was to determine how many US adolescents did not initiate the HPV vaccine during 2015-2018 because their parents had concerns regarding the vaccine’s safety. We also analyzed vaccine adverse event reporting data, in parallel, to understand if the public sentiment of HPV vaccine safety is in alignment with evidence from the vaccine safety surveillance system.  (more…)
Author Interviews, HPV, JAMA, OBGYNE / 16.09.2021

MedicalResearch.com Interview with: Helen Trottier Ph.D Assistant Professor, Department of Social and Preventive Medicine, Researcher, CHU Sainte-Justine Research Center Université de Montréal Montréal, Québec, Canada MedicalResearch.com: What is the background for this study? Response: We know that HPV infection can have serious consequences such as the development of cancerous lesions in the cervix. HPV infection is also very prevalent in young women of childbearing age but the possible consequences of HPV in pregnancy have been poorly studied. Some population registers around the world have shown a reduction in the risk of preterm birth with HPV mass vaccination, but we must be careful with this kind of ecological correlation. We have set up a large cohort study in pregnant women to study the association between HPV in pregnancy and preterm birth by targeting certain HPV genotypes and the duration of the infection. (more…)
Author Interviews, Cancer Research, HPV, JAMA, Vaccine Studies / 07.09.2021

MedicalResearch.com Interview with: Yuehan (Jenny) Zhang, ScM PhD Candidate in Cancer Epidemiology Johns Hopkins Bloomberg School of Public Health MedicalResearch.com: What is the background for this study? Response: Human Papillomavirus (HPV) is the most common sexually transmitted infectious virus worldwide. Oral HPV infection has resulted in a continual increase in the incidence of oropharynx cancer over the past two decades in the US. New HPV infections are preventable with vaccines, which first entered use in the US in 2006. (more…)
Author Interviews, COVID -19 Coronavirus, JAMA, Vaccine Studies / 03.09.2021

MedicalResearch.com Interview with: Jeffrey M. Wilson MD Assistant Professor of Medicine Allergy and Immunology University of Virginia MedicalResearch.com: What is the background for this study? What are the main findings? Response: To date there have been few head-to-head studies evaluating the immune responses to COVID-19 vaccines. Here we measured IgG antibodies to the SARS-CoV-2 spike-RBD in adults who received full vaccination with either the Pfizer/BioNTech or Moderna vaccine. Our study is distinguished from many others because we developed a quantitative test with a read-out in standardized units (expressed as micrograms/mL). We found that antibody levels to the SARS-CoV-2 spike receptor-binding domain were lower in recipients of the Pfizer/BioNTech than Moderna vaccine. The difference in the antibody levels between vaccines was most evident in relatively older subjects. (more…)
Author Interviews, COVID -19 Coronavirus, Vaccine Studies / 02.09.2021

MedicalResearch.com Interview with: David H. Canaday, MD Associate Director of Research Geriatric Research, Education and Clinical Center (GRECC),  Cleveland VA Professor, Division of Infectious Disease, Case Western Reserve University Cleveland, Ohio MedicalResearch.com: What is the background for this study? Response: We were interested in following up on a prior study where we determined that nursing home residents, and in particular those that were given the Pfizer shot who never had COVID-19 in the past, had 4 fold less antibodies against the key Spike protein of the coronavirus than did the group of health care workers who were the other group studied. We wanted to see how those antibodies levels in these groups held up over 6 months.  (more…)
Author Interviews, Biomarkers, COVID -19 Coronavirus, JAMA / 28.08.2021

MedicalResearch.com Interview with: Laura Holberger, PhD Vice President, Strategic Partnerships Biolabs MedicalResearch.com: What is the background for this study? Response: Dr. Laura Holberger is the lead author of a JNO article published today describing the results of a research study done on behalf of BioLabs, a global network of coworking laboratory spaces, and the Cambridge Consortium for Rapid COVID Tests (CCRCT). BioLabs co-sponsored the study which helped validate a high-frequency testing protocol using an antigen test for COVID-19 under development by E25Bio Inc., a biotechnology company that develops rapid tests for infectious diseases.  The study involved twice-weekly testing of members and affiliates working in person at coworking laboratories in Cambridge and Boston, Massachusetts from September 2020 through March 2021. (more…)
Author Interviews, COVID -19 Coronavirus, Critical Care - Intensive Care - ICUs, Lancet, Pulmonary Disease / 26.08.2021

MedicalResearch.com Interview with: Jie Li, PhD, RRT, RRT-ACCS, RRT-NPS, FAARC Department of Cardiopulmonary Sciences Division of Respiratory Care Rush University, Chicago MedicalResearch.com: What is the background for this study? Response: Prone positioning has been shown to improve oxygenation and reduce mortality in intubated patients with acute respiratory distress syndrome (ARDS), as placing patients on their stomachs can help open alveoli and reduce ventilation to perfusion mismatch. At early pandemic, clinicians tried prone positioning for non-intubated patients with COVID-19 and found improvement in oxygenation. However, the evidence for patient outcomes such as intubation or mortality is still lacking. Thus we organized this international, multicenter, randomized controlled meta-trial, with 41 hospitals in 6 countries participated. (more…)
Author Interviews, Duke, JAMA, Nursing, Sexual Health, STD / 12.08.2021

MedicalResearch.com Interview with: Vincent Guilamo-Ramos, PhD MPH, LCSW, RN, ANP-BC, PMHNP-BC, AAHIVS, FAAN Vincent Guilamo-Ramos is dean and professor at the Duke University School of Nursing, vice chancellor for nursing affairs, Duke University, and director of the Center for Latino Adolescent and Family Health (CLAFH) at Duke. Dr. Guilamo-Ramos served as a member of the National Academies of Sciences, Engineering, and Medicine (National Academies) Committee on Prevention and Control of STIs in the U.S. that wrote the recent consensus study report. He also serves as a member of the Presidential Advisory Council on HIV/AIDS (PACHA) and the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. MedicalResearch.com: What is the background for this study? Response: The National Academies of Sciences, Engineering, and Medicine (National Academies) recently released a consensus study report on prevention and control of sexually transmitted infections (STIs) in the United States. The report entitled “Sexually Transmitted Infections: Adopting a Sexual Health Paradigm” includes a strong emphasis on adolescents and young adults as an important priority population for the response to record-level STI rates that have reached an all-time high for the sixth year in a row in 2019. The report also highlights the well-supported and crucial role of parents in addressing STIs and promoting sexual health among adolescents and young adults. In this new Viewpoint article, my co-authors and I, who contributed to the National Academies report as committee members or consultants, discuss the practical implications for health care professionals of engaging parents in adolescent sexual health services. (more…)
COVID -19 Coronavirus, PLoS / 07.08.2021

MedicalResearch.com Interview with: Melanie Bell, PhD, MS Professor Mel and Enid Zuckerman College of Public Health The University of Arizona MedicalResearch.com: What is the background for this study? Response: In May 2020 my colleagues began a cohort study called CoVHORT, which  aimed to investigate the impacts of the SARS-Cov-2 pandemic among residents of Arizona. The current study on long covid is a sub-study which included all CoVHORT participants who had a confirmed positive COVID-19 test, were not hospitalized, and had symptom data 30 days are longer since the test. We wanted to investigate the prevalence of long covid, also known as post-acute sequalae of COVID-19 (PASC) amongst people who did not experience severe acute infection. Although the definition is still evolving in the research community, we defined PASC as continuing to experience at least one symptom 30 days or longer post-acute infection. (more…)
Author Interviews, COVID -19 Coronavirus, Occupational Health, Weight Research / 01.08.2021

MedicalResearch.com Interview with: https://www.newtopia.com/Jeff Ruby, JD, MBA, Founder and Chief Executive Officer Leonard Fensterheim, MPH Vice President of Analytics MedicalResearch.com: What is the background for this study? What are common weight-change findings during the pandemic?  Obesity has been linked to increased risk of serious complications and the need for costly medical utilization – all of which has been exacerbated by the COVID-19 pandemic. There has been an increase of imposed restrictions that impact healthy lifestyles – the closing of gyms as an example – leading to additional stress and the complete disruption of daily lives. It’s no surprise that many people have gained weight since the beginning of the pandemic. According to the Centers for Disease Control and Prevention (CDC), before the pandemic, about 40% of Americans had obesity in the United States. This was already an alarming figure, but given that the American Psychological Association found that 42% of U.S. adults report undesired weight gain, with an average gain of 29 lbs. since the start of the pandemic, we expect that percentage has continued to grow. Against this backdrop, Newtopia sought to evaluate the impact of a guided habit change program on weight loss for 12 months during the COVID-19 pandemic. Method:
  • This was a retrospective study that looked at 1436 participants who began participating in the Newtopia experience in early 2020.
  • This analysis focused on weight change and was restricted to those participants with a body mass index >
  • 52% of participants were female, and the average age of the total study population was 46.5 years old (±10.6).
  • The percentage of participants with a 4.3% weight reduction after 12 months was assessed. This has been shown to be associated with meaningful reduction in healthcare costs.
  • The average weight loss and the percentage BMI decrease was also assessed.
  Outcomes:
  • 77% of participants lost weight.
  • 44% of participants had a weight loss of >3%.
  • Average weight loss was 4.2% (p<.0001).
  • 22% of obese participants dropped a BMI category.
Despite the challenges of the Covid-19 pandemic, individuals participating in the Newtopia habit change experience still achieved impactful weight loss. (more…)
Author Interviews, Cognitive Issues, COVID -19 Coronavirus, Imperial College, Lancet / 28.07.2021

MedicalResearch.com Interview with: Dr. Adam Hampshire PhD Faculty of Medicine Department of Brain Sciences Imperial College London MedicalResearch.com: What is the background for this study? Response: During 2020 I was leading a study that sought to map the distribution of cognitive abilities and aspects of mental health across the UK population. The study generated a lot of interest because it was a collaboration with BBC2 Horizon, leading to ~390,000 participants. When the pandemic began to escalate in the UK a number of my colleagues at Imperial and elsewhere contacted me to note that the study could be used to investigate the impact of both the pandemic and direct illness on daily life, mental health and cognition. I had been thinking along similar lines so decided to add questionnaires about peoples' experiences with the pandemic and Covid-19 illness. (more…)
Allergies, Author Interviews, COVID -19 Coronavirus, JAMA, Vaccine Studies, Vanderbilt / 27.07.2021

MedicalResearch.com Interview with: Kimberly G. Blumenthal, MD, MSc Massachusetts General Hospital The Mongan Institute Boston, MA 02114 Matthew S. Krantz, MD Division of Allergy, Pulmonary and Critical Care Medicine Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee   MedicalResearch.com: What is the background for this study? Response: During the initial COVID-19 vaccine campaign with healthcare workers in December 2020, there was an unexpected higher than anticipated rate of immediate allergic reactions after Pfizer and Moderna mRNA vaccines.  This prompted both patient and provider concerns, particularly in those with underlying allergic histories, on the associated risks for immediate allergic reactions with the mRNA vaccines. Because of the significantly improved effectiveness of two doses of an mRNA vaccine compared to one dose, it was important to determine if those who experienced immediate allergic reaction symptoms after their first dose could go on to tolerate a second dose safely.    (more…)
Author Interviews, Cancer Research, COVID -19 Coronavirus, JAMA, Prostate Cancer, Race/Ethnic Diversity / 23.07.2021

MedicalResearch.com Interview with: Andres F. Correa, MD Assistant Professor Department of Surgical Oncology, and Adrien Bernstein, MD Second Year Urologic Oncology Fellow Fox Chase Cancer Center MedicalResearch.com: What is the background for this study? Response: Unfortunately, it has been well-established that historically Black Americans experience increased cancer specific mortality compared to white patients. In prostate cancer specifically studies have shown that when access to care is equitable this gap resolves. This suggests that biological factors are not driving these differences but rather the result of the complex interplay of social determinants and systemic inequities in our healthcare system. Early in the pandemic, multiple studies demonstrated that minority communities disproportionately shouldered poor COVID-19 outcomes.  On March 13th 2020, the American College of Surgeons recommended against elective procedures; however, the definition of an elective oncologic case was left to the discretion of the provider. As prostate cancer treatment can be safely deferred up to a year follow diagnosis, management of prostate cancer during the initial lockdown period of the COVID-19 Pandemic provided a useful analysis of the differential restrictions placed on non-emergent health care during the Pandemic. (more…)
Author Interviews, COVID -19 Coronavirus, JAMA / 15.07.2021

MedicalResearch.com Interview with: Michael Ohl, MD, MSPH Associate Professor of Internal Medicine-Infectious Diseases Roy J. and Lucille A. Carver College of Medicine University of Iowa MedicalResearch.com: What is the background for this study? Response: The background is that remdesivir was approved for treatment in 2020 largely based on the results of the Adaptive COVID-19 Treatment Trial 1 (ACTT-1), which found that remdesivir treatment was associated with more rapid recovery from illness among people hospitalized with COVID-19. The intention was that - even if remdesivir did not lead to substantial improvements in survival-  it could help people to recover more quickly and be discharged from hospital sooner, potentially opening scare hospital pends to treat more patients during the pandemic.   (more…)
Author Interviews, Infections / 11.07.2021

MedicalResearch.com Interview with: Juliana Menezes MSc “I am a PhD student at the Faculty of Veterinary Medicine of the University of Lisbon. I do my research at the Centre for Interdisciplinary Research in Animal Health under the Supervision of Professor Constança Pomba, the head of the Antibiotic Resistance Lab. The Idea for this work came from my supervisor, that has been working in the field of antibiotic resistance for a while and was leading a research project, the Pet-Risk consortium (http://petrisk.fmv.ulisboa.pt/) which main goal was to evaluate sharing of resistant bacteria between animal and humans (namely ESBL). Following this idea, we thought that would be important to evaluate colistin resistance in animals.” MedicalResearch.com: What is the background for this study? Response: With the global spread of multi-drug carbapenem resistant Gram-negative bacteria, colistin is a last-resort antimicrobial to treat ICU patients in hospitals. Thus, WHO has classified Colistin as a Highest Priority Critically Important Antimicrobial for human medicine, therefore, resistance represents a serious concern among physicians and scientists.  Increasing trends and prevalence of colistin resistance have been observed worldwide, and the studies are mainly focused on food-producing animals or hospitalized humans, suggesting an exchange of pathogenic bacteria and/or mobile genetic elements between different reservoirs. The rational for this study is the importance to evaluate colistin resistance in companion animals as they are living in direct contact with humans in the community. (more…)
Author Interviews, CDC, COVID -19 Coronavirus, Heart Disease, JAMA, UCSD / 01.07.2021

MedicalResearch.com Interview with: Margaret Ryan MD MPH Medical Director of Defense Health Agency Immunization Healthcare Division Pacific Region Office, San Diego CA Clinical Professor at the University of California San Diego MedicalResearch.com: What is the background for this study? What are the main findings? Response: Military clinicians, especially those in the Defense Health Agency Immunization Healthcare Division, first became aware of a few cases of myocarditis following COVID-19 vaccination in early Feb 2021.  These cases included young men who presented with chest pain a few days after 2nd dose of mRNA (Pfizer or Moderna) vaccine.  As more young people became eligible for 2nd doses of vaccine, more cases were identified.  By late April, the military had identified 23 cases of myocarditis, with remarkably similar presentations, after COVID-19 vaccination.  This case series is described in the current issue of JAMA Cardiology. (more…)
Author Interviews, COVID -19 Coronavirus, Environmental Risks / 30.06.2021

MedicalResearch.com Interview with: Els M. Broens DVM, PhD, Dipl. ECVM, EBVS European Veteirnary Specialist in Veterinary Microbiology Associate Professor / Director VMDC Department Biomolecular Health Sciences (Clinical Infectiology) Faculty of Veterinary Medicine | Utrecht University MedicalResearch.com: What is the background for this study? Response: Several events have demonstrated that SARS-CoV-2 can infect animals, felines and mustelids in particular. In companion animals these are currently considered to be incidents with a negligible risk for public health since the main force of the pandemic is transmission between humans. However, it is urgent to understand the potential risk of animal infections for public health in the later stages of the pandemic when SARS-CoV-2 transmission between humans is greatly reduced and a virus reservoir in animals could become more important. Incidental cases have shown that COVID-19 positive owners can transmit SARS-CoV-2 to their dog or cat. The close contact between owners and their dogs and cats and the interaction between dogs and cats from different households raises questions about the risk for pets to contract the disease and also about role of these animals in the transmission of SARS-CoV-2. (more…)
Author Interviews, COVID -19 Coronavirus, Vaccine Studies / 22.06.2021

MedicalResearch.com Interview with: Dr Boby Varkey Maramattom MD,DM, FRCP, FRCPE Fellow in Critical care neurology (Mayo Clinic) Lead Consultant Neurologist Aster Medcity, Kochi, Kerala Associate Director- Clinical Research Centre, Aster Medcity. Convener, Neurocritical care subsection Indian academy of Neurology  (IAN) MedicalResearch.com: What is the background for this study? Response:  Approximately 2-3 months after the vaccination programme commenced in India, we began to notice an uptick in the incidence of Guillain-Barré Syndrome (GBS) in our community. All the cases that presented to us during this period had almost the same clinical presentation. They presented within a few days ( usually within 1-2 weeks) of the first dose of the ChAdOx1-S/nCoV-19 vaccine. Most of the patients were women and it seemed to involve the middle aged to elderly age groups. As a result of this observation, we started to compile the clinical findings of these patients and collate them. (more…)
Author Interviews, Infections / 22.06.2021

MedicalResearch.com Interview with: Dr. Rafael Kroon Campos PhD Department of Microbiology and Immunology University of Texas Medical Branch Galveston, TX MedicalResearch.com: What is the background for this study? What are the main findings? Response: The COVID-19 pandemic is affecting millions of people. COVID-19 is a disease that primarily affects the lungs, but it also affects other organs and tissues, including heart and olfactory receptors. There is a growing body of evidence showing that COVID-19 can affect reproductive health by reducing androgen hormones, sperm counts and causing pain and discomfort in the testes. The virus that causes this disease is named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is unknown whether these symptoms are caused by direct virus testes infection or a byproduct of the immune system fighting the virus. (more…)
COVID -19 Coronavirus / 15.06.2021

MedicalResearch.com Interview with: Jonathan Baktari, MD CEO of e7health.com Dr. Baktari, CEO discusses the COVID-19 Delta COVID-19 variant and his insights into pandemic concerns and control. MedicalResearch.com: What is meant by the 'Delta' variant?  Are there differences in the clinical presentation or complications?  Response: Variants are now given Greek lettering for everyone and the Delta variant represents the variant from India. Pulmonary reports indicate it is much more contagious and there are reports of increased hospitalization with this variant.  MedicalResearch.com: Where is the variant currently found and where is it likely to spread? Response: Obviously India, but it has taken over as the dominant strain in England and it is about 6% of the strains in the United states and growing. (more…)